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Telomerase treatment prevents lung profibrotic
pathologies associated with physiological aging
Sergio Piñeiro-Hermida1, Chiara Autilio2, Paula Mart́ınez1, Fátima Bosch3, Jesús Pérez-Gil2, and Maria A. Blasco1
Short/dysfunctional telomeres are at the origin of idiopathic pulmonary fibrosis (IPF) in patients mutant for telomere
maintenance genes. However, it remains unknown whether physiological aging leads to short telomeres in the lung, thus
leading to IPF with aging. Here, we find that physiological aging in wild-type mice leads to telomere shortening and a reduced
proliferative potential of alveolar type II cells and club cells, increased cellular senescence and DNA damage, increased
fibroblast activation and collagen deposits, and impaired lung biophysics, suggestive of a fibrosis-like pathology. Treatment of
both wild-type and telomerase-deficient mice with telomerase gene therapy prevented the onset of lung profibrotic
pathologies. These findings suggest that short telomeres associated with physiological aging are at the origin of IPF and that a
potential treatment for IPF based on telomerase activation would be of interest not only for patients with telomerase
mutations but also for sporadic cases of IPF associated with physiological aging.
Introduction
Telomeres are protective structures at the ends of eukaryotic
chromosomes that are essential for chromosome stability
(Blackburn, 2001). In mammals, telomeric DNA consists of
TTAGGG repeats bound by a six-protein complex termed
“shelterin” (Liu et al., 2004; de Lange, 2005). Telomeres shorten
due to the incomplete replication of DNA ends with each cell
division, a phenomenon known as the “end-replication” prob-
lem (Watson, 1972; Olovnikov, 1973). Telomere shortening can
be compensated through the de novo addition of telomeric re-
peats onto chromosome ends by telomerase, a reverse tran-
scription composed of a catalytic subunit (TERT) and an RNA
component (Terc) used as a template for telomere elongation
(Greider and Blackburn, 1985). Critically short telomeres with
aging are considered one of primary hallmarks of aging, since
they can trigger other hallmarks of aging, such as genomic
instability, cellular senescence, and apoptosis, mitochondrial
dysfunction and loss of the regenerative capacity of tissues
(Blasco, 2005; Blackburn et al., 2006; López-Ot́ın et al., 2013). In
the case of the lungs, aging causes a progressive impairment of
lung function, including structural and immunological alter-
ations that can impair the respiratory function and increase the
risk of lung diseases (Lowery et al., 2013; Brandenberger and
Mühlfeld, 2017). Indeed, aging is the main risk factor for de-
veloping chronic lung diseases, such as chronic obstructive
pulmonary disease, lung cancer, and idiopathic pulmonary fi-
brosis (IPF; López-Ot́ın et al., 2013; Meiners et al., 2015).
IPF affects ∼3 million people worldwide with a median sur-
vival time from diagnosis of 2–4 yr (Martinez et al., 2017;
Richeldi et al., 2017; Raghu et al., 2018). As the major risk factor
for IPF is age (Raghu et al., 2011; Faner et al., 2012; Selman and
Pardo, 2014), its global incidence is predicted to increase in
association with the worldwide phenomenon of demographic
aging (Ley and Collard, 2013). In agreement with IPF being an
age-associated disease, IPF patients present most of the hall-
marks of aging including abnormal shortening of telomeres,
genomic instability, mitochondrial dysfunction, increased oxi-
dative stress, and senescence (Meiners et al., 2015; Selman and
Pardo, 2014; Alder et al., 2008; Demopoulos et al., 2002; Bueno
et al., 2015; Korfei et al., 2013).
Interestingly, between 8% and 15% of familial IPF cases
are associated with mutations in telomerase or in telomere-
protective proteins (Alder et al., 2008; Armanios et al., 2007;
Tsakiri et al., 2007). In agreement with defects in telomere
maintenance and accelerated telomere shortening being at the
origin of these familial IPF cases, these patients show abnor-
mally short telomeres (Alder et al., 2008; Armanios et al.,
2007). Mutations in telomerase genes have been observed in
1–3% of sporadic cases of pulmonary fibrosis (Tsang et al., 2012;
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Armanios and Blackburn, 2012; Armanios, 2013). Even in the
absence of telomerase mutations, IPF patients are reported to
have shorter telomeres than healthy individuals (Alder et al.,
2008). Moreover, genome-wide association studies revealed
that single nucleotide polymorphisms within the Tert gene in-
crease the risk of lung fibrosis (Fingerlin et al., 2013; Codd et al.,
2013). Thus, mutations in telomere maintenance genes are as-
sociated with the clinical manifestations of IPF (Alder et al.,
2008; Armanios et al., 2007; Tsakiri et al., 2007; Fingerlin
et al., 2013; Cronkhite et al., 2008; Chibbar et al., 2010) and
other respiratory pathologies (Snetselaar et al., 2015; Stanley
et al., 2015).
Short telomeres have been previously shown by us and
others to impair stem cell function and tissue regeneration
(Mart́ınez and Blasco, 2011; Flores et al., 2005; Sharpless and
DePinho, 2007). In the case of the lung, stem cell and pro-
genitor compartments include bronchial SCGB1A1+ club cells
and SFTPC (surfactant protein C)+ alveolar type II (ATII) cells
(Rawlins et al., 2009; Kotton and Morrisey, 2014; Hogan et al.,
2014). In the past, we showed that induction of telomere dys-
function specifically in ATII cells was sufficient to induce pro-
gressive and lethal pulmonary fibrosis in mice, demonstrating
that dysfunctional telomeres ATII cells are at the origin of IPF
(Povedano et al., 2015). We further demonstrated that the
presence of short telomeres in lung cells triggered IPF in
telomerase-deficient mice upon treatment with a low dose of the
lung-damaging agent bleomycin, which did not induce fibrosis
in wild-type mice. Interestingly, treatment with a telomerase
gene therapy that activated telomerase in the lungs was suffi-
cient to stop the progression of fibrosis in these mice (Povedano
et al., 2018). Together, evidence from human patients andmouse
models with short telomeres indicates that short/dysfunctional
telomeres are at the origin of fibrosis.
However, it remains unknown whether physiological aging
also leads to short telomeres in the lung and whether this in-
creases the risk of IPF with aging. To address this, here we study
telomere length and lung phenotypes both in wild-type and
telomerase-deficient mice with increasing age. Furthermore, we
address whether telomerase gene therapy could delay or prevent
lung profibrotic phenotypes associated with physiological aging
in wild-type and telomerase-deficient mice.
Results
Physiological aging leads to decreased ATII and club cells in
the lungs of wild-type mice, and this is anticipated in
telomerase-deficient mice
We first set out to address whether physiological aging in wild-
type mice leads to lung pathologies. To this end, we performed
a full characterization of mouse lungs at different ages (5,
8–9, 42–49, and 92–125 wk of age) in both wild-type and
third-generation (G3) telomerase-deficient mice with short te-
lomeres (Blasco et al., 1997) as a control for lung pathologies
associated with accelerated telomere shortening (Fig. 1, A and B).
We could obtain very old (92–125 wk) Tert+/+ mice, but not G3
Tert−/− mice, owing to the fact that the latter have a shortened
life span (Herrera et al., 1999a). First, we measured telomere
length in the alveolar parenchyma and bronchi by performing
an immuno–telomere quantitative FISH (Q-FISH) to measure
telomere fluorescence intensity and the prosurfactant protein C
and CC10 antibodies as markers for ATII and club cells, re-
spectively. Immuno–telomere Q-FISH was performed on lung
sections from both Tert+/+ and G3 Tert−/−mice at different ages to
measure telomeres in ATII and club cells with aging (Povedano
et al., 2018; Canela et al., 2007; Flores et al., 2008). We deter-
mined both mean telomere fluorescence (mean telomere spot
intensity) as an indication of the mean telomere length and the
percentage of short telomeres corresponding to the 20th per-
centile of the telomere fluorescence intensity values of controls
(5-wk-old Tert+/+ mice). We found a gradual decrease in mean
telomere fluorescence in ATII and club cells with increasing age
in the lungs of Tert+/+mice (Fig. 1, C, D, and G). Interestingly, this
decrease in mean telomere fluorescence in ATII and club cells
was already detectable at young age in G3 Tert−/− compared with
age-matched Tert+/+ mice, and very old Tert+/+ mice (92–125 wk)
showed low telomere fluorescence similar to that of young
5-wk-old G3 Tert−/−mice (Fig. 1, C, D, and F). Also, the percentage
of short telomeres in ATII and club cells was progressively
increased with increasing age in Tert+/+ mice and was already
elevated in G3 Tert−/− mice at young ages compared with age-
matched Tert+/+ mice (Fig. 1, E and G). Together, these results
demonstrate telomere shortening with age in the lungs of wild-
type mice, reaching at old ages values similar to those of young
G3 Tert−/− mice.
Next, we set out to determine whether telomere shortening
with aging in Tert+/+ mice lead to defects in the lung homeo-
stasis. To this end, we quantified different lung cell types pre-
viously shown to be important for lung regeneration, such as
ATII cells (positive for the surfactant protein C–SFTPC marker)
and club cells (positive for the secretoglobin 1A1-SCGB1A1
marker; Giangreco et al., 2002; Rock et al., 2011; Guha et al.,
2012; Desai et al., 2014). We found that physiological aging
leads to a progressive decrease both in the proportion of SFTPC-
positive ATII cells relative to the total number of alveolar cells
and in the number of SCGBA1-positive club cells per epithelium
length both in wild-type and G3 Tert−/− mice (Fig. 1, C, H, and I).
Again, G3 Tert−/− mice already showed this reduction at young
ages compared with age-matched Tert+/+ mice, and at 42–49 wk,
G3 Tert−/− mice showed a reduction in ATII cells and club cells
that was equivalent to very old (92–125-wk-old) Tert+/+ mice
(Fig. 1, C, H, and I).
Aging leads to fibroblast activation and collagen deposits in
wild-type lungs and this is anticipated in telomerase-deficient
lungs
One of the phenotypes associated with lung degenerative pa-
thologies is the presence of fibrosis. Thus, we next set out to
explore the presence of profibrotic phenotypes in both Tert+/+
and G3 Tert−/− mice associated with physiological aging. We
found that both Tert+/+ and G3 Tert−/−mice showed a progressive
increment with age in the expression of vimentin, a marker of
fibroblasts in the alveolar parenchyma (Fig. 2, A and B). At 42–49
wk of age, G3 Tert−/− mice showed a significantly higher per-
centage of vimentin-positive area per high-power field (HPF;
Piñeiro-Hermida et al. Journal of Cell Biology 2 of 20
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Figure 1. Telomerase deficiency and natural aging in the mouse lung leads to telomere shortening and reduction in the number of ATII and club cells.
(A and B) Generation of Tert+/+ and G3 Tert−/− mice and scheme of lung tissue harvesting. (A) Heterozygous Tert+/− mice were crossed to obtain Tert+/+ and
G1 Tert−/− mice, and successive crosses between G1 Tert−/− and then G2 Tert−/− mice were made to generate G3 Tert−/− mice. (B) Scheme of sacrifice and
collection of lungs from Tert+/+ and G3 Tert−/−mice at different time points. (C) Representative images showing a Q-FISH for telomere spot fluorescence in ATII
and club cells (Cy3Tel probe [red], SFTPC- and SCGB1A1-positive cells [green]) and nuclei stained with DAPI (blue; left and center right), SFTPC (brown, red
arrowheads; center left), and SCGB1A1 (brown, green arrowheads; right) immunostainings in lung sections from Tert+/+ and G3 Tert−/− at different time points.
(D–I) Quantification of mean telomere fluorescence (mean spot intensity; D and F), percentage of short telomeres in ATII and club cells corresponding to the
20th percentile of the fluorescence intensity values of controls (5-wk-old Tert+/+ mice; E and G), and SFTPC-positive ATII cells (%) and SCGB1A1-positive club
cells per epithelium length (millimeters; H and I). Quantifications were performed on five different alveolar areas or bronchi in a random way. Data are
Piñeiro-Hermida et al. Journal of Cell Biology 3 of 20
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40× field) than age-matched Tert+/+ mice and similar to those
of very old (92–125-wk-old) Tert+/+ mice (Fig. 2, A and B),
suggesting anticipation of this phenotype in the absence of
telomerase activity. Next, we studied fibroblast activation
by analyzing the peribronchial expression of the smooth
muscle actin (SMA) marker. We found that the percentage of
expressed as mean ± SEM (n = 4 animals per group). *, P < 0.05; **, P < 0.01; ***, P < 0.001 (Shapiro–Wilk, Kruskal–Wallis, and Dunn–Sidak multiple
comparison test). ns, not significant.
Figure 2. Premature aging by accelerated telomere shortening and natural aging in the mouse lung result in increased fibroblast presence and
activation and collagen deposition. (A) Representative images showing vimentin (brown; left) and SMA (brown; center left) immunostainings and Sirius Red
(red; center right) and Masson (blue; right) stainings in lung sections from Tert+/+ and G3 Tert−/− mice at different time points. (B–E) Quantification of vimentin
(fibroblast marker)–positive area per HPF (%; B), peribronchial SMA (fibroblast activation marker) –positive area (%; C), alveolar collagen content per HPF (%;
D), and peribronchial collagen content (%; E). Quantifications were performed on five different alveolar areas or bronchi in a randomway. Data are expressed as
mean ± SEM (n = 4 animals per group). *, P < 0.05; **, P < 0.01; ***, P < 0.001 (Shapiro–Wilk, Kruskal–Wallis, and Dunn–Sidak multiple comparison test). ns,
not significant.
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peribronchial SMA-positive area gradually increased with age
in Tert+/+ and G3 Tert−/− mice, with G3 Tert−/− mice showing
significantly more SMA positivity at 8–9 and 42–49 wk of age
compared with age-matched Tert+/+mice (Fig. 2, A and C). Again,
very old Tert+/+ mice (92–125 wk of age) showed the same SMA
positivity as 42–49-wk-old G3 Tert−/− mice (Fig. 2, A and C). In
agreement with increased peribronchial fibroblast activation, we
also found increased collagen deposits in the peribronchial areas
(Masson’s trichrome staining) and alveolar areas (Sirius Red)
with increasing age in both Tert+/+ and G3 Tert−/− mice, with
G3 Tert−/− mice showing an anticipation of the phenotype with a
similarly high percentage of alveolar and peribronchial collagen
content in 42- to 49-wk-old G3 Tert−/− mice compared with very
old (92–125-wk-old) wild-type mice (Fig. 2, A, D, and E).
Aging leads to increased DNA damage, apoptosis, and
senescence in wild-type lungs, and this is anticipated in
telomerase-deficient mice
Accumulation of cells with DNA damage is associated with ag-
ing, as well as with the presence of short telomeres in mice
(López-Ot́ın et al., 2013; Herrera et al., 1999b; Samper et al.,
2001; Bernardes de Jesus et al., 2012). A marker for double-
stranded DNA breaks and dysfunctional telomeres is phospho-
rylation of γ-H2AX (D’adda et al., 2003; Takai et al., 2003). Here,
we set out to quantify γ-H2AX–positive cells in the lungs of
Tert+/+ and G3 Tert−/− mice at different ages. We observed in-
creased γ-H2AX–positive cells per HPF with age in the alveolar
parenchyma both in Tert+/+ and G3 Tert−/− mice, with G3 Tert−/−
mice showing an anticipation of the phenotype at all ages and
with 42–49-wk-old G3 Tert−/− mice reaching levels similar to
very old (92–125-wk-old) wild-type mice (Fig. 3, A and B). Next,
we determined apoptosis in lung alveolar parenchyma as mea-
sured by presence of activated caspase-3 (C3)–positive cells.
Again, we found an increased number of C3-positive cells with
age in both Tert+/+ and G3 Tert−/− mice, with G3 Tert−/− mice
showing an anticipation of the phenotype at all ages andwith 42-
to 49-wk-old G3 Tert−/− mice reaching levels similar to very old
(92–125-wk-old) wild-type mice (Fig. 3, A and C).
Finally, we also measured presence of alveolar p16-positive
cells, which are associated with senescence. Notably, we found
an increase in p16-positive cells with age in the lungs of Tert+/+ and
G3 Tert−/− mice (Fig. 3, A and D). Interestingly, both Tert+/+ and
G3 Tert−/− mice showed an increased number of senescent mac-
rophages (F4/80-p16–positive cells) with aging, with 42–49-wk-
old G3 Tert−/− mice showing the same percentage of macrophages
positive for p16 as very old (92–125-wk-old) wild-typemice (Fig. 3,
A and E). The percentages of alveolar senescent cells positive for
the macrophage marker F4/80 were 85.72% (8–9-wk-old Tert+/+
mice), 88.24% and 89.59% (42–49-wk-old Tert+/+ and Tert−/− mice,
respectively), and 73.18% (92–125-wk-old Tert+/+mice), suggesting
that most of the alveolar senescent cells were macrophages.
Aging leads to decreased proliferation of ATII and club cells in
wild-type lungs, and this is anticipated in the absence of
telomerase
As we observed increased DNA damage and senescence with
aging in total lung cells, we next addressed proliferation of
different lung cell types with aging in both Tert+/+ and G3 Tert−/−
mice. To this end, we performed double immunostainings of
whole-lung sections with the proliferation marker Ki67 and the
cell-specific markers SFTPC (ATII cells), SCGB1A1 (club cells),
and F4/80 (alveolar macrophages [AMs]). In addition, we also
performed double immunostainings with the differentiation
marker SOX2 and SCGB1A1 (club cells) to detected differentia-
tion of club cells both in Tert+/+ and G3 Tert−/− mice at different
ages (Fig. 4 A). We found a gradual reduction in proliferating
ATII cells and club cells with increasing age in Tert+/+ mice,
which at 92–125 wk of age reached similarly low levels as 42–49-
wk-old G3 Tert−/− mice (Fig. 4, A, B, and D). We obtained similar
findings in the case of F4/80-positive AMs (Fig. 4, A and C).
Interestingly, we also found that differentiation of club cells
(SOX2-positive club cells) progressively increased with age in
both Tert+/+ and G3 Tert−/− lungs, with G3 Tert−/− lungs showing
significantly more differentiated Sox2-positive club cells at 8–9
wk old and 42–49 wk old compared with wild-type mice, which
at very old age (92–125 wk old) had similarly high levels of Sox2-
positive cells as 42–49-wk-old G3 Tert−/− mice (Fig. 4, A and E).
To confirm Tert deficiency in G3 Tert−/− lungs, we analyzed
Tert mRNA expression levels in total lung extracts of young
(5 wk) and older (61–72 wk) Tert+/+ and G3 Tert−/− mice. As ex-
pected, Tert mRNA expression was negligible in young and
old G3 Tert−/− mice compared with age-matched Tert+/+ mice
(Fig. 4 F). Additionally, sincemacrophages have been recognized
to play a significant role in IPF pathogenesis (Zhang et al., 2018),
we assessed mRNA expression of markers of M1 (Tnf, Il1b, and
Il6) and M2 (Il4, Il10, and Il13) macrophages in total lung extracts
from young and older Tert+/+ and G3 Tert−/−mice (Fig. 4, G–L). In
general, a significant increase in the expression of thesemarkers
was anticipated in G3 Tert−/− compared with Tert+/+ mice (Fig. 4,
G–L). These results were supported by analysis of TNF, inter-
leukin (IL)-6, IL-4, and IL-10 protein levels in lung homogenates
(Fig. 4, M–P). In general, protein levels of these cytokines were
significantly increased in young and old G3 Tert−/− mice com-
pared with Tert+/+ mice. Remarkably only IL-10 protein levels
increased with the age in both G3 Tert−/− and Tert+/+mice (Fig. 4,
M–P).
Impaired pulmonary surfactant activity in aged wild-type
lungs is anticipated in telomerase-deficient mice
We next set out to address the potential age-derived biophysical
changes in lung surfactant activity in both Tert+/+ and G3 Tert−/−
mice. To do so, we tested the biophysical properties of pulmo-
nary surfactant isolated from bronchoalveolar lavages in a cap-
tive bubble surfactometer (Autilio and Pérez-Gil, 2019).
The adsorption and postexpansion adsorption (Fig. 5 A) into
air–liquid interfaces of surfactant were both significantly better
in the youngest Tert+/+ mice (4–7 wk old) compared with G3
Tert−/− mice of several ages. However, the difference in surface
active properties disappeared with increasing age of Tert+/+
mice, from 23 wk on. Interestingly, 71–72-wk-old Tert+/+ mice
showed a further impairment in surfactant properties during
dynamic cycles when comparedwith younger Tert+/+mice (4–7 or
23–34 wk old; Fig. 5 B). Once subjected to breathing-like con-
ditions, physiological aging affected the capability of surfactant to
Piñeiro-Hermida et al. Journal of Cell Biology 5 of 20
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achieve γ values <9 mN/m under the conditions tested, leading to
high relative area of compression (Fig. 5 B) and low stability of
interfacial films (Fig. S1 A). This reduced surfactant activity was
anticipated in G3 Tert−/− mice that already showed an early
worsening in the relative area of compression at 4–7 wk of age
(Fig. 5 B). Similarly, at 23 wk of age, G3 Tert−/− mice presented a
significantly higher minimum γ when compared with Tert+/+
mice of the same age (Fig. 5 B).
The content in surfactant proteins SP-B and SP-C also tended
to decrease in G3 Tert−/− mice with increasing age (Fig. S1 B). As
described for both healthy mice (Mahavadi et al., 2010) and
neonates without lung disease (Autilio et al., 2020), the levels of
SP-B and SP-C at the extracellular lavage exhibit a substantial
variability in the control group. Moreover, the extreme hydro-
phobicity of SP-B and SP-C and their strong association with
lipids typically make their Western blot (WB) bands appear
Figure 3. Induced-telomere shortening and natural aging increase DNA damage, apoptosis, and macrophage senescence in the mouse lung.
(A) Representative immunostainings for alveolar γ-H2AX (brown, green arrowheads; left), activated C3 (brown, orange arrowheads; center left), p16 (brown,
blue arrowheads; center right), and F4/80 and p16 (purple and brown, respectively; red arrowheads indicate double F4/80-p16-positive AMs; right) in Tert+/+
and G3 Tert−/− mice at different time points. (B–D) Quantification of alveolar γ-H2AX–positive (B) and C3- positive (C), and p16-positive (D) cells, and double
F4/80-p16-positive AMs (%; E). Quantifications were performed on five different alveolar areas in a random way. Data are expressed as mean ± SEM (n = 4
animals per group). *, P < 0.05; **, P < 0.01; ***, P < 0.001 (Shapiro–Wilk, Kruskal–Wallis, and Dunn–Sidak multiple comparison test). ns, not significant.
Piñeiro-Hermida et al. Journal of Cell Biology 6 of 20
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Figure 4. Premature telomere shortening and natural aging reduce the proliferation of ATII cells, macrophages, and club cells and increase the
differentiation of club cells. (A) Representative immunostainings for SFTPC (purple), F4/80(brown), and Ki67 (blue; orange and blue arrowheads indicate
Piñeiro-Hermida et al. Journal of Cell Biology 7 of 20
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blurred, especially in the case of SP-C. In spite of this limitation,
we could detect a significantly lower amount of the two proteins
in the lung fluid at 23–34 wk of age, becoming only a trend when
71–72-wk-old Tert+/+ and G3 Tert−/− mice were compared. This
confirms a worsening in surfactant biophysical properties dur-
ing physiological aging regardless of Tert presence, since sur-
factant proteins are required to stabilize the respiratory surface
and facilitate breathing mechanics.
double SFTPC-Ki67– and F4/80-Ki67–positive cells, respectively; left); SCGB1A1 (purple) and Ki67 (blue and green arrowheads indicate double SCGB1A1-
Ki67–positive club cells; center), and SCGB1A1 (blue) and SOX2 (brown; red arrowheads indicate double SCGB1A1-SOX2–positive club cells; right) in Tert+/+ and
G3 Tert−/− mice at different time points. (B–E) Quantification of SFTPC-Ki67–positive (B), F4/80-Ki67–positive (C), SCGB1A1-Ki67–positive (D), and SCGB1A1-
SOX2–positive (E) cells. (F–L) Changes in total lung mRNA expression levels of Tert (F) and total lung mRNA expression of Tnf (G), Il1b (H), and Il6 (I; pro-
inflammatory markers) and Il4 (J), Il10 (K), and Il13 (L; anti-inflammatory markers) normalized to 18S expression, and (M–P) protein levels of TNF (M), IL-6 (N),
IL-4 (O), and IL-10 (P) assessed in lung homogenates from young (5 wk) and older (61–72 wk) Tert+/+ and G3 Tert−/− mice. Quantifications were performed on
five different alveolar areas or bronchi in a random way. Data are expressed as mean ± SEM (n = 4 animals per group). *, P < 0.05; **, P < 0.01; ***, P < 0.001
(Shapiro–Wilk, Kruskal–Wallis, and Dunn–Sidak multiple comparison test). ns, not significant.
Figure 5. Physiological aging leads to impaired surfactant activity which is partially restored by telomerase gene therapy in bothwild-type mice and
telomerase-deficient mice. (A and B) Captive bubble results from Tert+/+ and G3 Tert−/− mice with increasing weeks of age. (C and D) Captive bubble results
from 71–72-wk-old Tert+/+ and G3 Tert−/− mice treated with AAV9-empty or AAV9-Tert. (A and C) Top: Surface tension obtained 1 s after applying surfactant
onto the air bubble (initial adsorption). Bottom: Surface tension obtained 1 s after the bubble expansion (postexpansion [PE] adsorption). (B and D) Top:
Representative γ-relative area isotherms obtained under breathing-like dynamic cycles for each group tested. Bottom: Minimum andmaximum γ along with the
relative area of compression obtained during the 20th cycle. White bars represent Tert+/+ mice. Gray bars represent G3 Tert−/− mice. Data are expressed as
mean ± SEM (n = 5–6 animals per group). *, P < 0.05; **, P < 0.01. Between different ages for each condition: One-way ANOVA with post hoc Dunn–Sidak
multiple comparison test. Between different conditions within the same age: following a Shapiro–Wilk normality test, two-sample unpaired t test, or
Mann–Whitney test when appropriate. γ, surface tension; max, maximum; min, minimum.
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Telomerase gene therapy prevents lung fibrotic-like
phenotypes in wild-type and telomerase-deficient mice
We previously showed that activation of telomerase in the
lung using adeno-associated serotype 9 vector (AAV9)–Tert gene
therapy vectors was sufficient to stop the progression of lung
fibrosis in a mouse model of lung fibrosis owing to the presence
of short telomeres and a sublethal dose of the lung-damaging
agent bleomycin (Povedano et al., 2018). The fact that we show
here that physiological aging leads to lung profibrotic pheno-
types in wild-type mice that are anticipated in the context of
telomerase-deficiency mice suggests that these phenotypes
originate from telomere shortening with aging and that telo-
merase activation therapy should prevent or delay them.
Thus, here we set out to test whether telomerase gene ther-
apy could delay or prevent lung profibrotic phenotypes associ-
ated with physiological aging in wild-type mice. As control, we
also treated with telomerase gene therapy telomerase-deficient
mice with short telomeres. To this end, 27–30-wk-old Tert+/+ and
G3 Tert−/− mice received an intravenous injection of either
AAV9-Tert or AAV9-null virus particles, and these mice were
followed until their end point (week 21; Fig. 6 A). First, we
measured total lung mRNA expression of Tert by quantitative
PCR (qPCR) to confirm Tert overexpression in these mice. We
found that both Tert+/+ and G3 Tert−/− mice treated with AAV9-
Tert showed significantly increased TertmRNA levels 21 wk after
treatment compared with the corresponding mice treated with
the AAV9-null vectors (Fig. 6 B). Next, we determined telomere
length in the alveolar parenchyma and bronchi of these mice using
immuno–telomere Q-FISH to evaluate the mean telomere fluores-
cence (mean telomere spot intensity) and the percentage of short
telomeres in the indicated cell types. We found that both Tert+/+ and
G3 Tert−/− mice treated with AAV9-Tert showed increased mean
telomere fluorescence and significantly decreased percentage of
short telomeres in ATII and club cells compared with the corre-
spondingmice treatedwith theAAV9-null vectors (Fig. 6, C–F and I).
Next, we set out to study whether AAV9-Tert treatment
rescued the numbers of ATII cells and club cells in the lung by
performing immunostainings with SFTPC and SCGB1A1, re-
spectively. We found that both Tert+/+ and G3 Tert−/− mice
treated with AAV9-Tert showed significantly increased numbers
of ATII and club cells (Fig. 6, G–I), indicating a recovery of lung
cellularity. The increased number of ATII cells in wild-type mice
upon treatment with AAV9-Tert was confirmed by increased
transcriptional levels of different surfactant genes produced by
ATII cells, including Sftpa1, Sftpb, and Sftpd, compared with
AAV9-null–treated wild-type mice (Fig. 6, J–L). In the case of
G3 Tert−/− mice treated with AAV9-Tert, we observed a tendency
toward an increase in the expression of these genes, but this was
not statistically significant (Fig. 6, J–L).
Telomerase gene therapy prevents fibrotic-like phenotypes in
aged wild-type and telomerase-deficient mice
Next, we set out to address whether treatment with telomerase
gene therapy also prevented fibrotic phenotypes with aging in
both Tert+/+ and G3 Tert−/− mice. We found that both Tert+/+ and
G3 Tert−/− mice treated with AAV9-Tert showed significantly
decreased numbers of fibroblasts in the lung, as indicated by a
decreased percentage of vimentin-positive area per HPF com-
pared with the corresponding cohorts treated with the null
vector (Fig. 7, A and B).We also detected a significant decrease in
fibroblast activation by reduced percentage of peribronchial
SMA-positive area in both Tert+/+ and G3 Tert−/− mice treated
with AAV9-Tert compared with the corresponding cohorts
treated with the null vector (Fig. 7, A and C). Finally, we also
observed a decreased percentage of alveolar collagen content per
HPF (Sirius Red) and peribronchial collagen content deposits
(Masson’s trichrome staining) in both Tert+/+ and G3 Tert−/−
mice treated with AAV9-Tert compared with the corresponding
cohorts treated with the null vector (Fig. 7, A, D, and E).
Telomerase gene therapy prevents DNA damage, senescence,
and apoptosis in agedwild-type and telomerase-deficient mice
lungs
Next, we determined the impact of AAV9-Tert gene therapy in
rescuing DNA damage, apoptosis, and senescence in Tert+/+ and
G3 Tert−/− lungs treated with either AAV9-Tert or AAV9-null virus
particles (Fig. 8). We found that both Tert+/+ and G3 Tert−/− mice
treated with AAV9-Tert showed significantly decreased numbers
of γ-H2AX–positive cells per HPF in the lung parenchyma com-
pared with the corresponding cohorts treated with the null vector
(Fig. 8, A and B), indicating decreased DNA damage upon telo-
merase treatment. Similarly, we detected significantly decreased
numbers of activated caspase3-positive cells in the alveolar pa-
renchyma of both Tert+/+ and G3 Tert−/− lungs treated with AAV9-
Tert compared with those treated with the null vector (Fig. 8, A
and C). Interestingly, increased senescence as detected by p16-
positive cells specifically in the case of AMs was also rescued in
both Tert+/+ and G3 Tert−/− lungs treated with AAV9-Tert com-
pared with those treated with the null vector (Fig. 8, A, D, and E).
Finally, by performing double immunostainings with the
proliferation marker Ki67 and the specific markers SFTPC (ATII
cells), SCGB1A1 (club cells), and F4/80 (AMs), we observed that
proliferation of ATII cells, club cells, and AMs was significantly
increased in both Tert+/+ and G3 Tert−/− lungs treated with
AAV9-Tert compared with those treated with the null vector
(Fig. 9, A–D). Interestingly, the number of SOX2-positive dif-
ferentiating club cells was also significantly reduced in Tert+/+
and Tert−/− lungs upon telomerase gene therapy (Fig. 9, A and E).
Finally, to address whether treatment with telomerase gene
therapy also prevented expression of proinflammatory and anti-
inflammatorymarkers, we determinedmRNA expression of Tnf,
Il1b, Il6, Il4, Il10, and Il13 in total lung extracts from Tert+/+ and
G3 Tert−/− mice (Fig. 9, F–K). We observed significantly de-
creased expression of these markers in both Tert+/+ and
G3 Tert−/− mice treated with AAV9-Tert compared with those
treated with the null vector (Fig. 9, F–K). These findings were
also supported by decreased protein levels of TNF, IL-6, IL-4, and
IL-10 in lung homogenates from Tert+/+ and G3 Tert−/−mice upon
treatment with AAV9-Tert (Fig. 9, L–O).
Telomerase gene therapy prevents age-related impairment of
surfactant activity in wild-type and telomerase-deficient mice
Finally, we addressed whether treatment with telomerase gene
therapy improves age-related pulmonary surfactant inactivation
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Figure 6. Telomerase gene therapy in the mouse lung results in telomere elongation and increased number of ATII and club cells. (A) Experimental
protocol for the administration of AAV9-Tert and AAV9-empty virus. 27–30-wk-old Tert+/+ and G3 Tert−/− mice were administered with 2E12vg of AAV9-Tert
Piñeiro-Hermida et al. Journal of Cell Biology 10 of 20
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in both Tert+/+ and G3 Tert−/−mice. To that end, we compared the
activity of surfactant obtained from 71- to 72-wk-old G3 Tert−/−
and Tert+/+ mice treated with AAV9-empty or AAV9-Tert. We
found that telomerase gene therapy significantly improved
surfactant interfacial properties of old mice. G3 Tert−/− mice
treated with AAV9-Tert showed an enhanced surfactant ad-
sorption with reduced relative area of compression during dy-
namic cycles (Fig. 5, C and D) when compared with the animals
treated with AAV9-empty. Similarly, surfactant from Tert+/+ mice
treatedwith telomerase exhibited a significant decrease in relative
area of compression (Fig. 5 D) compared with AAV9-empty group.
Interestingly, telomerase gene therapy did not change SP-B
and SP-C content in G3 Tert−/−mice but significantly reduced the
amount of SP-B in Tert+/+ mice (Fig. S2 B), with a tendency to
decrease SP-C content. This may be due to a therapy-mediated
rebalance of surfactant homeostasis that is more evident when
endogenous Tert is also present.
Discussion
In spite of the recent introduction of two new antifibrotic drugs
for the treatment of IPF, pirfenidone and nintedanib, there is
still no cure for IPF, a devastating chronic progressive interstitial
lung disease with a poor prognosis, with a median survival from
the time of diagnosis of <4 yr (Richeldi et al., 2017; Martinez
et al., 2017; Raghu et al., 2018; Somogyi et al., 2019). Thus,
and AAV9-empty virus by intravenous tail injection. Animals were sacrificed 21 wk later for lung tissue harvesting. (B) Total lung mRNA levels of Tert nor-
malized to 18S expression in AAV9-empty– and AAV9-Tert–treated animals. (C–H) Quantification of mean telomere fluorescence (mean spot intensity; C and
E), percentage of short telomeres in ATII and club cells corresponding to the 20th percentile of the fluorescence intensity values of controls (5-wk-old Tert+/+
mice; D and F), and SFTPC-positive ATII cells (%) and SCGB1A1-positive club cells per epithelium length (millimeters) in AAV9-Tert– and AAV9-empty–treated
mice (G and H). (I) Representative images showing a Q-FISH for telomere spot fluorescence in ATII and club cells (Cy3Tel probe [red], SFTPC- and SCGB1A1-
positive cells [green], and nuclei stained with DAPI [blue]; left and center right), and SFTPC (brown, red arrowheads; center left) and SCGB1A1 (brown, green
arrowheads; right) immunostainings in lung sections from Tert+/+ and G3 Tert−/−mice treated with the AAV9-Tert (upper panels) or AAV9-empty (lower panels)
virus. (J–L) Changes in total lung mRNA expression levels of the surfactant markers Sftpa1, Sftpc, and Sftpd normalized to 18S expression. Quantifications were
performed on five different alveolar areas or bronchi in a random way. Data are expressed as mean ± SEM (n = 4 animals per group). *, P < 0.05; **, P < 0.01;
***, P < 0.001 (Shapiro–Wilk, Kruskal–Wallis, and Dunn–Sidak multiple comparison test). ns, not significant.
Figure 7. AAV9-Tert treatment reduces fibroblast presence and activation and collagen deposition in the mouse lung. (A) Representative images of
vimentin (brown; left) and SMA (brown; center left) immunostainings and Sirius Red (red; center right) and Masson (blue; right) stainings in lung sections from
Tert+/+ and G3 Tert−/−mice treated with the AAV9-Tert (upper panels) or AAV9-empty (lower panels) virus. (B–E)Quantification of vimentin-positive (fibroblast
marker) area per HPF (%; B), peribronchial SMA-positive (fibroblast activation marker) area (%; C), alveolar collagen content per HPF (%; D), and peribronchial
collagen content (%; E). Quantifications were performed on five different alveolar areas or bronchi in a random way. Data are expressed as mean ± SEM (n = 4
animals per group). **, P < 0.01; ***, P < 0.001 (Shapiro–Wilk, Kruskal–Wallis and Dunn–Sidak multiple comparison test). ns, not significant.
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additional hypotheses on the origin of IPF are necessary to drive
new, more effective therapeutic approaches. Indeed, pirfeni-
done and nintedanib show anti-inflammatory and antifibrotic
activity and slow IPF progression, but they are not curative
(Ahluwalia et al., 2014; King et al., 2014; Hunninghake, 2014;
Karimi-Shah and Chowdhury, 2015). We have recently demon-
strated that AAV9-Tert therapy prevents the progression of
pulmonary fibrosis in a mouse model of pulmonary fibrosis
owing to presence of short telomeres (Povedano et al., 2018), thus
demonstrating that short telomeres are at the origin of pulmonary
fibrosis in mice and that elongation of short telomeres by telo-
merase can prevent progression of the disease. Remarkably, we
did not find any deleterious effects of AAV9-Tert gene therapy in
mice. In particular, we previously reported that AAV9-Tert gene
therapy resulted in a significant increase in median and maxi-
mum life span accompanied by an amelioration of various age-
associated phenotypes, including delayed cancer (Bernardes de
Jesus et al., 2012). Moreover, we recently demonstrated AAV9-
Tert therapy did not lead to an increase in cancer incidence or
earlier onset of cancer in mice (Muñoz-Lorente et al., 2018).
In this regard, cellular aging is likely to be at the origin of IPF,
as suggested by the fact that the incidence of IPF increases with
age (Raghu et al., 2011; Faner et al., 2012; Selman and Pardo,
2014). Telomere shortening with age is considered one of the
primary hallmarks of aging, and the presence of critically short
telomeres owing to mutations in telomerase genes is associated
with familial cases of IPF (Alder et al., 2008; Armanios et al.,
2007; Tsakiri et al., 2007; Fingerlin et al., 2013; Cronkhite et al.,
2008; Chibbar et al., 2010). A role for short/dysfunctional telo-
meres at the origin of IPF is also supported by genetically
modified mouse models with mutations in telomerase or telo-
mere maintenance genes (Povedano et al., 2015; Liu et al., 2018).
In particular, we previously showed that a low bleomycin dose
that does not induce pulmonary fibrosis in wild-type mice
synergizes with short telomeres to trigger full-blown progress-
ive pulmonary fibrosis in telomerase-deficient mice (Povedano
et al., 2015). Similarly, induction of acute telomere dysfunction
by abrogation of an essential telomere-protective protein, TRF1,
specifically in ATII cells of the lung, is sufficient to induce
progressive and lethal IPF in mice (Povedano et al., 2015). Thus,
both in human patients and in mouse models, short/dysfunc-
tional telomeres can induce IPF. Furthermore, ATII cells have
been identified as a relevant cell type at the origin of the disease
(Povedano et al., 2015).
To date, however, it remains uncertain whether physiological
aging also leads to significant telomere shortening in the lungs
Figure 8. Telomerase gene therapy ameliorates DNA damage, apoptosis, and macrophage senescence in the mouse lung. (A) Representative im-
munostainings for alveolar γ-H2AX (brown, green arrowheads; left), activated C3 (brown, orange arrowheads; center left), p16 (brown, blue arrowheads; center
right), and F4/80 and p16 (purple and brown, respectively; red arrowheads indicate double F4/80-p16–positive AMs; right) in lungs of Tert+/+ and G3 Tert−/−
mice treated with the AAV9-Tert (upper panels) or AAV9-empty (lower panels) virus. (B–E) Quantification of alveolar γ-H2AX–positive (B), C3-positive (C), and
p16-positive (D) cells and double F4/80-p16–positive AMs (%; E). Quantifications were performed on five different alveolar areas in a random way. Data are
expressed as mean ± SEM (n = 4–5 animals per group). *, P < 0.05; **, P < 0.01; ***, P < 0.001 (Shapiro–Wilk, Kruskal–Wallis and Dunn–Sidak multiple
comparison test). ns, not significant.
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Figure 9. Treatment with AAV9-Tert restores the proliferation of AT II cells, macrophages, and club cells and reduces the differentiation of club
cells. (A) Representative immunostainings for SFTPC (purple), F4/80 (brown), and Ki67 (blue; orange and blue arrowheads indicate double SFTPC-Ki67– and
F4/80-Ki67–positive cells, respectively; left); SCGB1A1 (purple) and Ki67 (blue; green arrowheads indicate double SCGB1A1-Ki67–positive club cells; center);
and SCGB1A1 (blue) and SOX2 (brown; red arrowheads indicate double SCGB1A1-SOX2–positive club cells; left) in lungs of Tert+/+ and G3 Tert−/− mice treated
with the AAV9-Tert (upper panels) or AAV9-empty (lower panels). (B–E) Quantification of SFTPC-Ki67–positive (B), F4/80-Ki67–positive (C), SCGB1A1-
Ki67–positive (D), and SCGB1A1-SOX2–positive (E) cells. (F–K) Changes in total lung mRNA expression levels of Tnf (F), Il1b (G), and Il6 (H; proin-
flammatory markers) and Il4 (I), Il10 (J), and Il13 (K; anti-inflammatory markers) normalized to 18S expression and (L–O) protein levels of TNF (L), IL-6 (M), IL-4
(N), and IL-10 (O) assessed in lung homogenates from AAV9-empty– and AAV9-Tert–treated animals. Quantifications were performed on five different alveolar
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and could be at the origin of a number of cases of sporadic IPF. In
this regard, patients with sporadic IPF show shorter telomeres
than normal healthy individuals (Tsang et al., 2012; Armanios
and Blackburn, 2012; Armanios, 2013), and mice also show
shorter telomeres in the lungs with increasing age (Birch et al.,
2015). Here, we report that physiological aging inwild-typemice
leads to telomere shortening in SCGB1A1-positive club cells
and SFTPC-positive ATII cells, a phenomenon that is anticipated
in telomerase-deficient mice (Tert−/− mice). In addition, we ob-
serve both reduced numbers and reduced proliferation of club
cells and ATII cells with aging in wild-type mice, and again
this phenotype is anticipated in telomerase-deficient mice.
These findings suggest that telomere shortening associated with
physiological aging can impair the stemness of bronchial club
cells and ATII cells, which was previously shown to have epi-
thelial stem/progenitor properties (Giangreco et al., 2002;
Rawlins et al., 2009; Rock et al., 2011; Guha et al., 2012; Hogan
et al., 2014; Kotton and Morrisey, 2014; Desai et al., 2014). Thus,
these results presented here support the notion that telomere
shortening with aging can impair the ability of stem cells to
regenerate tissues (Blasco, 2007; Flores et al., 2008).
Further supporting this, we find here a significant increase of
differentiating SOX2-positive club cells with aging, which again
was anticipated in the telomerase-deficient mice. Sox2 has been
previously shown a marker of differentiation of club cells
(Tompkins et al., 2009), which is increased in bleomycin-
induced pulmonary fibrosis in mice (Chuang et al., 2018), as
well as in patients suffering from IPF (Plantier et al., 2011).
Interestingly, we also find here that mouse aging results in a
reduced proliferation of the lung resident AMs and increased
expression of M1 and M2 macrophage markers. Tissue-resident
AMs are the most numerous immune cells present in the lung
and have a key role in lung homeostasis by protecting the lung
during tissue damage (Higashimoto et al., 1993; Boyd et al., 2012;
Hussell and Bell, 2014; Byrne et al., 2015; Wong et al., 2017;
Angelidis et al., 2019). Specifically, M1 macrophages contribute
to tissue injury after excessive production of proinflammatory
mediators (e.g., TNF, IL-1B, and IL-6), and M2 macrophages lead
to resolution of inflammation and tissue repair upon anti-
inflammatory cytokine activation (e.g., IL-4, IL-10, and IL-13;
Zhang et al., 2018; Liu et al., 2019). M2 macrophages were re-
ported to promote myofibroblast differentiation and are asso-
ciated with pulmonary fibrogenesis (Hou et al., 2018). In this
sense, overexpression of IL-6 and IL-10 were reported to impact
the polarization of profibrotic M2 macrophages (Sun et al., 2011;
Ayaub et al., 2017). In addition, IL-4 and IL-13 are required for
the maintenance of pulmonary fibrosis (Jakubzick et al., 2003).
In line with shorter telomeres, wild-type mouse lungs show
increased DNA damage, senescence, and apoptosis, together
with an impairment in surfactant biophysical activity with in-
creasing age, and this is anticipated in telomerase-deficient
mice. Previous authors have also suggested a role for senes-
cence in IPF (Selman and Pardo, 2014; Spagnolo et al., 2015;
Pardo and Selman, 2017; Campisi, 2013). In particular, the effects
observed on ATII and club cells in Tert−/− mice could be self-
autonomous and/or a consequence of a different cellular envi-
ronments. Indeed, senescent cells secrete inflammatory cyto-
kines, chemokines, growth factors, and remodeling proteins that
have autocrine and paracrine effects on the tissue microenvi-
ronment (Acosta et al., 2008; Kuilman et al., 2008; Parikh et al.,
2019). As previously described by us, telomerase-deficient mice
secret higher cytokine levels than wild-type mice (Mosteiro
et al., 2016).
It is of particular interest that the majority of senescent cells
were found to be AMs that have a crucial role in maintaining the
correct surfactant homeostasis, preventing the accumulation of
already used surfactant at the air–liquid interface with a limited
biophysical performance (Autilio and Pérez-Gil, 2019). An im-
pairment of surfactant activity has been already proposed as an
early marker of fibrosis in a model of bleomycin-induced fi-
brosis in mice (Lopez-Rodriguez et al., 2016). It is therefore
conceivable that the intrinsic deficiency in operative surfactant,
both as a consequence of deactivated material that is not prop-
erly cleared by aged macrophages and the lack of enough
amounts of newly synthetized surfactant by a reduced popula-
tion of type II cells, leads to a progressively impaired pulmonary
mechanics contributing ultimately to reduction in lung tissue
elasticity and its abnormal remodeling.
Of relevance, we detected significantly increased collagen
deposits with increasing age in wild-type lungs suggestive of
early stages of IPF, which was anticipated in telomerase-deficient
mice, again highlighting the role of short telomeres in the origin
of these pathological findings. This is interesting, because pre-
vious studies have failed to detect lung fibrosis in the telomerase-
deficient mouse model (Liu et al., 2007; Lee et al., 2009; Degryse
et al., 2012).
Together, these molecular, cellular, biophysical, and patho-
logical findings support that telomere shortening associated
with wild-typemouse aging could be at the origin of fibrotic-like
pathologies in mice. Here, we further demonstrate this hy-
pothesis by rescuing these lung phenotypes at the molecular,
cellular, biophysical, and pathological levels using an AAV9-
based telomerase (Tert) gene therapy strategy, which has been
previously shown by us to transduce lung cells, including ATII
cells, and elongate telomeres (Povedano et al., 2018), as well as to
block the progression of IPF in a mouse model of IPF which
combined presence of short telomeres owing to telomerase de-
ficiency and damage to the lungs using a low dose of bleomycin
that did not induce IPF in wild-typemice (Povedano et al., 2015).
In particular, treatment of old wild-type mice with AAV9-Tert
rescued the proliferative defects of club cells, ATII cells, and
resident AMs and rescued senescence, apoptosis, DNA damage,
and pulmonary surfactant activity, as well as all signs of fibrosis,
in aged wild-type mice.
In summary, here we demonstrate that telomerase gene
therapy prevents the onset of lung degenerative and profibrotic
areas or bronchi in a random way. Data are expressed as mean ± SEM (n = 4–5 animals per group). *, P < 0.05; **, P < 0.01; ***, P < 0.001 (Shapiro–Wilk,
Kruskal–Wallis, and Dunn–Sidak multiple comparison test). ns, not significant.
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pathologies associated with physiological aging in wild-type and
telomerase-deficient mice. These findings contribute to a better
understanding of the importance of TERT as a potential target
for future therapeutic approaches in IPF, especially in patients in
whom pulmonary fibrosis is associated with short telomeres.
Materials and methods
Mice and ethical statement
Tert heterozygous mice were generated as previously described
(Liu et al., 2000) and backcrossed to >98% C57/BL6 background.
Tert+/− mice were intercrossed to generate Tert+/+ and first-
generation (G1) homozygous Tert−/− knockout mice. Second-
generation (G2) Tert−/− mice were generated by successive
breeding of G1 Tert−/− and then G3 Tert−/− mice by crosses be-
tween G2 Tert−/− mice (Fig. 1 A). Finally, Tert+/+ and G3 Tert−/−
mice were used for aging experiments for which lungs of these
mice where collected at different time points (Fig. 1 B). These
mice were also used for telomerase gene therapy assays (Fig. 6
A). Experimental groups were composed by male (70%) and
female (30%) mice in the case of molecular, cellular and path-
ological characterization. In addition, only male mice were used
for the biophysical characterization. It should be noted that no
significant differences were found between sexes in any of the
experiments performed (data not shown). All animals were bred
and maintained under specific pathogen–free conditions in
laminar flow caging at the Spanish National Cancer Centre an-
imal facility in accordance with the recommendations of the
Federation of European Laboratory Animal Science Associations.
All animal procedures were approved by the CNIO Institutional
Animal Care and Use Committee and the Ethics Committee for
Research and Animal Welfare.
Viral particle production and treatment
Viral vectors were generated by triple transfection of HEK293
cells and purified as previously described (Matsushita et al.,
1998; Ayuso et al., 2010). Cells were cultured in roller bottles
(Corning) in DMEM supplemented with 10% FBS to 80% con-
fluence and cotransfected with a plasmid carrying the expres-
sion cassette flanked by the AAV2 viral inverted terminal
repeats, a helper plasmid carrying the AAV rep2 and cap9 genes,
and a plasmid carrying the adenovirus helper functions (plas-
mids kindly provided by K.A. High, Children’s Hospital of
Philadelphia, Philadelphia, PA). The expression cassettes were
under the control of the cytomegalovirus promoter and con-
tained a SV40 polyA signal for eGFP, and the cytomegalovirus
promoter and the 39-untranslated region of the Tert gene as
polyA signal for Tert. AAV9 particles were purified using two
cesium chloride gradients, dialyzed against PBS, filtered, and
stored at −80°C until use. Then, 27–30-wk old Tert+/+ and
G3 Tert−/− mice were administered with 2E12vg of AAV9-Tert
and AAV9-empty virus particles in a volume of 100 µl 0.001%
Pluronic F-68 in PBS 1X by a single intravenous tail injection
(Fig. 6 A). Pluronic F-68 was used to prevent aggregations of the
virus particles (Foust et al., 2009). Animals were then sacrificed
21 wk after the administration of the AAV9-Tert and AAV9-
empty virus particles.
Lung tissue collection and preparation
Before tissue collection, animals were euthanized by intraperi-
toneal injection of 10 µl/g of a ketamine/xylazine anesthetic
combination in saline (100:10 mg/kg, respectively). Following
dissection, lungs from Tert+/+ and G3 Tert−/− mice of the natural
aging groups were harvested, fixed in 4% formaldehyde, and
subsequently embedded in paraffin for histopathology and im-
munohistochemistry. In the case of Tert+/+ and G3 Tert−/− mice
destined for the telomerase gene therapy experiments, only the
lefts lungs were processed for histopathology and immunohis-
tochemistry, and right lung lobes were separated and snap fro-
zen in liquid nitrogen and stored at −80°C for qPCR.
Telomere Q-FISH analysis
After deparaffinization and rehydration, tissues underwent
antigen retrieval in 10 mM sodium citrate buffer, and per-
meabilization was performed in PBS 0.5% Triton X-100 for 3 h.
Next, tissues were washed three times for 5 min each in PBS 1X,
fixed in 4% formaldehyde for 5 min, washed three times for
5 min each in PBS, and dehydrated in a 70–90%–100% ethanol
series (5 min each). Following air drying the slides, 30 µl of the
telomere probe mix (10 mM TrisCl, pH 7.2, 25 mMMgCl2, 9 mM
citric acid, 82 mM Na2HPO4, 50% deionized formamide [Sigma-
Aldrich], 0.25% blocking reagent [Roche], and 0.5 µg/ml Telo-
meric PNA probe [Panagene]) was added, and slides were
incubated for 3 min at 85°C and then 1 h at room temperature in
a wet chamber in the dark. Slides were washed twice for 15 min
each in 10 mM TrisCl (pH 7.2) and 0.1% BSA in 50% formamide
and then three times for 5min each in TBS 0.08%Tween 20. The
tissues were then washed three times for 5 min each in PBS 0.1%
Triton X-100, blocked with 10% donkey serum in PBS 0.1%
Triton X-100 for 1 h, and incubated overnight at 4°C with rabbit
prosurfactant protein C (AB3786, 1:200; EMD Millipore) and
mouse CC10 (clone E-11, sc-365992, 1:200; Santa Cruz Biotech-
nology) antibodies. After three washes with PBS 0.1% Triton X-
100, tissues were incubated with secondary antibodies for 1 h,
washed three times for 5 min each in PBS 1X, and then mounted
with Vectashield mounting media with DAPI (Vector Laborato-
ries). Confocal images (40× magnification, 2× zoom, NA 1.25)
were acquired as stacks using an SP5-WLL confocal microscope
(Leica Microsystems), and maximum projection images were
created with the LAS AF 2.7.3.9723 software. Telomere signal
intensity was quantified using Definiens Developer Cell software
version XD 64 2.5. For each analysis, three visual fields per
section were scored.
Histopathological analyses and immunostaining
Paraffin-embedded lungs were cut into 3-µm sections for his-
topathological evaluation or immunohistochemistry. Sirius Red
(Sigma-Aldrich) and Masson’s trichrome (Dako) stainings were
performed following manufacturer guidelines for the quantifi-
cation of alveolar and peribronchial collagen content (%). Rabbit
vimentin (clone D21H3, 5741, 1:50; Cell Signaling Technology)
and mouse SMA (clone 1A4, IR611, 1:4; Dako and Agilent
Technologies) antibodies were used for the determination of
vimentin and peribronchial SMA-positive areas (%). Rabbit
prosurfactant protein C (AB3786, 1:100; EMDMillipore) and goat
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CC10 (clone T-18, sc-9772, 1:1,000; Santa Cruz Biotechnology)
antibodies were used to determine the number of SFTPC-
positive cells to total cell numbers (%) and the number of
SCGB1A1-positive cells per epithelium length (millimeters). Rat
F4/80 antibody (clone A3-1, MCA497, 1:20; AbD Serotec, and Bio-
Rad) was used to determine the number of F4/80-positive
macrophages. Mouse phospho-histone H2A.X (Ser139; clone
JBW301, 05–636, 1:20; EMD Millipore), rabbit cleaved C3
(Asp175; 9661, 1:300; Cell Signaling Technology), and rat p16
(clone 33B; CNIO Monoclonal Antibodies Core Unit, Madrid,
Spain) antibodies were used to assess the level of DNA damage
(%) of SFTPC-positive ATII cells (SFTPC/H2AX) and the apo-
ptosis and senescence rates (%) of SFTPC-positive ATII cells and
F4/80-positive macrophages (SFTPC/F4/80/C3, SFTPC/p16, and
F4/80/p16). Rabbit Ki-67 (clone D3B5, 12202, 1:50; Cell Signaling
Technology) and rabbit SOX2 (clone C70B1, 3728, 1:75; Cell Sig-
naling Technology) antibodies served to assess the level of pro-
liferation (%) of SFTPC- and SCGB1A1-positive ATII and club cells
and F4/80-positive macrophages (SFTPC/F4/80/Ki67 and
SCGB1A1/Ki67) and the degree of differentiation of SCGB1A1-
positive club cells (SCGB1A1/SOX2). All images (40× magnifica-
tion, 2× optical zoom, NA 1.20) were acquired using the optical
microscope Provis AX70 (Olympus) connected to a camera
Olympus PM-C35DX. Olympus cellSens Entry 1.18 software was
used to acquire images. Histological quantifications were per-
formed on five different alveolar areas or five different bronchi
in each case in a random way. The Fiji open-source image pro-
cessing software package (http://fiji.sc) was used to quantify
total cell numbers, epithelium length measurements, and the
percentage of DAB (color deconvolution), Sirius Red, and Mas-
son´s trichrome positive areas.
RNA isolation, reverse transcription, and qPCR
Inferior lung lobes from AAV9-Tert or AAV9-empty injected
animals were homogenized in TRIzol (Invitrogen), and total
RNA was treated with 2.72 KU/µl RNase-free DNase (Qiagen),
purified using an RNeasy Mini Kit (Qiagen), and reverse tran-
scribed to cDNA using SuperScript II First-Strand Synthesis
System (Invitrogen) following the manufacturer specifications.
The quantity and quality of total RNA was assessed on a Nano-
Drop Spectrophotometer (Thermo Fisher Scientific). cDNA
samples were then amplified by qPCR in triplicate reactions for
each primer pair assayed on a 7500 Real-Time PCR Instrument
(Applied Biosystems) using SYBR Premix Ex Taq (Takara Bio)
and the following qPCR conditions: 95°C for 2 min; 40 cycles of
95°C for 30 s, 60°C for 30 s and 95°C for 15 s, 60°C for 1 min, 95°C
for 15 s, and 60°C for 15 s. Results were normalized using 18S
rRNA gene (Rn18s) as endogenous control. The following primer
pairs were used: Tert-F (Forward), 59-TGACCAGCGTGTTAGGAA
GA-39; Tert-R (Reverse), 59 CAGGAGGAAAGGA GCCAGAG-39
(GenBank accession no. NM_009354.2); Tnf-F, 59-GCCTCTTCT
CATTCCTGCTTG-39; Tnf-R, 59-CTGATGAGAGGGAGGCCATT-39
(GenBank accession no. NM_013693.3); Il1b-F, 59-GCAACTGTT
CCTGAACTCAACT-39, Il1b-R 59-ATCTTTTGGGGTCCGTCAACT39
(GenBank accession no. NM_008361.3); Il6-F, 59-ACGGCCTTC
CCTACTTCACA-39 and Il6-R, 59-CATTTCCACGATTTCCCAGA-39
(GenBank accession no. NM_031168.1); Il4-F, 59-CCTCACAGC
AACGAAGAACA-39 and Il4-R, 59-CGAAAAGCCCGAAAGAGTC-39
(GenBank accession no. NM_021283.2); Il10-F, 59-GCACTACCA
AAGCCACAAGG-39 and Il10-R, 59-TAAGAGCAGGCAGCATAGCA-39
(GenBank accession no. NM_ 010548.2); Il13-F, 59-GCCTCCCCG
ATACCAAAAT-39 and Il13-R, 59-CTTCCTCCTCAACCCTCCTC-39
(GenBank accession no. NM_008355.3); Sftpa1-F, 59-CCATCG
CAAGCATTACAAAG-39 and Sftpa1-R, 59-CACAGAAGCCCCATC
CAG-39 (GenBank accession no. NM_023134.4); Sftpb-F, 59-CTG
CTGCTTCCTACCCTCTG-39 and Sftpb-R, 59-ATCCTCACACTCTTG
GCACA-39 (GenBank accession no. NM_147779.2); Sftpd-F, 59-
TGAGAATGCTGCCATACAGC-39 and Sftpd-R, 59-GAATAGACC
AGGGGCTCTCC-39 (GenBank accession no. NM_009160.2);
Rn18s-F, 59-ATGCTCTTAGCTGAGTGTCCCG-39 and Rn18s-R, 59-
ATTCCTAGCTGCGGTATCCAGG-39 (GenBank accession no. NR_
003278.3).
Pulmonary surfactant isolation and activity
Surfactant was collected from bronchoalveolar lavages of mice
lungs as described before (Autilio et al., 2018). In detail, bron-
choalveolar lavage supernatant was ultracentrifuged (100,000 g,
4°C, 1 h) and diluted with 5 mM Tris buffer containing 150 mM
NaCl (5 mM; pH 7; Sigma-Aldrich) to reach a concentration of
10 mg/ml of phosphatidylcholine (PC). PC was tested in tripli-
cate using an enzymatic colorimetric method (Spinreact; St.
Esteve de Bas).
The interfacial activity of surfactant was measured in a
captive bubble surfactometer as described before (Schürch et al.,
2010) upon injection of 300 nl surfactant onto the surface of the
air bubble. Initial adsorption was measured by monitoring the
decay in surface tension (γ) during the first 5 min after sur-
factant injection and postexpansion adsorption during the 5 min
after expansion of the bubble volume from0.05 to 0.15ml. Then,
the bubble was subjected to rapid (30 cycles/min) physiological-
like compression–expansion dynamics, changing its volume by
∼25%, and the corresponding isotherms were built upon rep-
resentation of γ versus relative area of the bubble. Surfactant
performance during cycling was evaluated by comparing mini-
mum and maximum γ and the reduction in area required to
reach the minimum γ. Finally, the mechanical stability of the
surfactant films was assessed by registering the decay in γ oc-
curring in compressed interfacial films as a consequence of the
discharge of five shocking mechanical perturbations as previ-
ously described (Schürch et al., 2010).
WB analysis
WB was performed under reducing conditions as previous de-
scribed (Lopez-Rodriguez et al., 2016). Since surfactant proteins
are the only proteins present in the complex, we normalize our
data, as previously reported (Autilio et al., 2020), by loading
onto the gel equivalent amounts of PC per sample (3 µg from
isolated mice surfactant). Therefore, changes in protein com-
position have to be interpreted as connected with changes in the
quality of surfactant, seen as protein-to-lipid ratios.
Electrophoresis Laemmli buffer (2% SDS, 62.5 mM Tris, pH
6.8, 10% glycerol, and 0.03% bromophenol blue) containing 4%
β-mercapto-ethanol was added to insolated mice surfactant be-
fore incubating (15 min; 90°C) and loading the samples. The
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polyacrylamide gel (16%) was run for ∼1 h, and proteins were
transferred onto polyvinylidene fluoride membranes with a
semi-dry system (1 h; 4°C) and blocked in PBS-T (100 mM
Na2HPO4/KH2PO4-1% Tween) with 5% skim milk at room tem-
perature for 2 h. Membranes were then incubated overnight
with the primary human/mouse polyclonal antibodies (1:5,000,
anti-mature SP-B [WRAB-48604], 1:10,000 anti-mature SP-C
[WRAB-76694; Seven Hills]) in PBS-T 5% milk at 4°C, washed
thoroughly in PBS-T, and incubatedwith the secondary antibody
(1:5,000, anti-rabbit [P0217]; Dako and Agilent) for 2 h at room
temperature (E3). Membranes were then developed (1 min of
exposition) using a commercial ECL system (Millipore). Bands
densitometry was performed by using ImageJ for Mac OS X.
ELISAs
Superior right lung lobes were homogenized in RIPA Buffer
(Thermo Fisher Scientific) containing a protease-phosphatase
inhibitor mixture (Roche), and total protein concentration was
determined with the Pierce BCA Protein Assay Kit (Thermo
Fisher Scientific). Cytokine levels were assessed in homogenized
lung tissue lysates using mouse IL-4, IL-10, IL-13, and TNF
Quantikine ELISA Kits (R&D Systems), following the manu-
facturer’s specifications, normalized to total lung protein levels.
Statistics
Statistical analyses were accomplished using SPSS Statistics
Software v21 for Windows (IBM). Following a Shapiro–Wilk
normality test, either a one-way ANOVA test or a Kruskal–
Wallis test were used, and then the post hoc Dunn–Sidak
multiple test was performed for multiple comparisons. Ac-
cording to the sample distribution, either a Mann–Whitney or
unpaired t test was used to compare Tert+/+ and G3 Tert−/−
mice of the same age or 71–72-wk-old mice with and without
telomerase therapy. Results are shown as mean values ± SEM.
For all analyses, a P value < 0.05 was considered statistically
significant.
Online supplemental material
Fig. S1 shows that the interfacial stability of surfactant material
from Tert+/+ mice under compression of the air–liquid interface
is significantly reduced after 71–72 wk of physiological aging.
Fig. S2 shows that telomerase therapy does not affect membrane
stability but apparently reduces the content of SP-B in Tert+/+
71–72-wk-old mice.
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thermia may improve surfactant function in asphyxiated neonates with
or without meconium aspiration syndrome. PLoS One. 13. e0192295.
https://doi.org/10.1371/journal.pone.0192295
Autilio, C., M. Echaide, S. Shankar-Aguilera, R. Bragado, D. Amidani, F. Sal-
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Supplemental material
Figure S1. Physiological aging leads to impaired surfactant activity in wild-type mice, and this is anticipated in telomerase-deficient mice. Interfacial
film stability and WB of hydrophobic surfactant proteins from Tert+/+ and G3 Tert−/− mice with increasing weeks of age. (A) Surface tension obtained after
hitting five-times-compressed surfactant membranes to test their stability. (B) SP-B and SP-C bands obtained by performing WB analysis in reducing con-
ditions, loading the same amount of PC for each sample. Densitometry analysis was performed using as reference the most intense band among the samples
tested within each run. White bars represent Tert+/+mice. Gray bars represent G3 Tert−/−mice. Data are expressed as mean ± SEM (n = 4–6 animals per group).
*, P < 0.05; **, P < 0.01 between different ages for each condition using one-way ANOVA with post hoc Dunn–Sidak multiple comparison test or between
different conditions within the same age following a Shapiro–Wilk normality test, two-sample unpaired t test, or Mann–Whitney test when appropriate. γ,
surface tension; A.D.U., arbitrary densitometry units.
Figure S2. Telomerase gene therapy prevents age-related worsening in surfactant activity in wild-type and telomerase-deficient mice. Membrane
stability andWB of hydrophobic surfactant proteins from 71–72-wk-old Tert+/+ and G3 Tert−/−mice treated with AAV9-empty or AAV9-Tert. (A) Surface tension
obtained after hitting five-times-compressed surfactant membranes to test their stability. (B) SP-B and SP-C bands obtained by performing WB analysis in
reducing conditions, loading the same amount of PC for each sample. Densitometry analysis was performed using as reference the most intense band among
the samples testedwithin each run.White bars represent Tert+/+mice. Gray bars represent G3 Tert−/−mice. Data are expressed asmean ± SEM (n = 3–5 animals
per group). *, P < 0.05 between different conditions following a Shapiro–Wilk normality test, two-sample unpaired t test, or Mann–Whitney test when
appropriate. γ, surface tension; A.D.U., arbitrary densitometry units.
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